After Today’s Big Decline, Is Hepion Pharmaceuticals, Inc. (HEPA)’s Near-Term Analysis Negative?

The stock of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) is a huge mover today! The stock decreased 4.67% or $0.135 during the last trading session, reaching $2.755. About 93,365 shares traded. Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) has declined 94.14% since September 11, 2018 and is downtrending. It has underperformed by 94.14% the S&P500.
The move comes after 9 months negative chart setup for the $8.80 million company. It was reported on Sep, 11 by Barchart.com. We have $2.56 PT which if reached, will make NASDAQ:HEPA worth $615,790 less.

More notable recent Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) news were published by: Globenewswire.com which released: “ContraVir Pharmaceuticals to Present CRV431 Phase 1 Data at the International Liver Congressâ„¢ – GlobeNewswire” on April 11, 2019, also Finance.Yahoo.com with their article: “The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq’s Good Books – Yahoo Finance” published on September 04, 2019, Benzinga.com published: “The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly’s Nasal Low Blood Sugar Drug – Benzinga” on July 25, 2019. More interesting news about Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) were released by: Globenewswire.com and their article: “Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431 – GlobeNewswire” published on August 14, 2019 as well as Benzinga.com‘s news article titled: “60 Biggest Movers From Friday – Benzinga” with publication date: August 19, 2019.

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. The company has market cap of $8.80 million. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. It currently has negative earnings. The firm was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.